CD8A and neoplasm: In addition, CD8+ T cells specific for the Gly to Val mutation led to the killing of cells from a HLA-A2 matched tumor cell line carrying the corresponding mutation, but not those cells carrying wild type RAS (Khleif et al. 1999).